Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy

BACKGROUND: Only a proportion of patients with bladder cancer may benefit from durable response to immune checkpoint inhibitor (ICI) therapy. More precise indicators of response to immunotherapy are warranted. Our study aimed to construct a more precise classifier for predicting the benefit of immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yi-Hui, Zhang, Jia-Xing, Chen, Xu, Liu, Fei, Cao, Jia-Zheng, Chen, Yu, Chen, Wei, Luo, Jun-Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371040/
https://www.ncbi.nlm.nih.gov/pubmed/34421886
http://dx.doi.org/10.3389/fimmu.2021.643282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371040/
https://www.ncbi.nlm.nih.gov/pubmed/34421886
http://dx.doi.org/10.3389/fimmu.2021.643282

Ejemplares similares